ESR1 and breast cancer: Figure 1 shows a positively staining tumor in comparison with a negative control. In the entire breast cancer cohort, the frequency of NY-ESO-1 expression was 13%. In TNBC it was 16%, and just 2% in ER+ (Table 2).